News
EFTRW
0.0290
-3.33%
-0.0010
Weekly Report: what happened at EFTRW last week (0422-0426)?
Weekly Report · 5h ago
Weekly Report: what happened at EFTRW last week (0415-0419)?
Weekly Report · 04/22 12:09
Weekly Report: what happened at EFTRW last week (0408-0412)?
Weekly Report · 04/15 11:59
Weekly Report: what happened at EFTRW last week (0401-0405)?
Weekly Report · 04/08 12:06
EFFECTOR THERAPEUTICS, INC. <EFTR.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $12 FROM $24
Reuters · 04/05 10:21
BUZZ-U.S. STOCKS ON THE MOVE-US banks, Hertz, Spirit,
Wall Street's main stock indexes advanced on Thursday. The Dow Jones Industrial Average was up 0.39% at 39,279.3. The top three S&P 500 percentage gainers were Enphase Energy, Delta Air Lines. The Nasdaq Composite was up 1.06%.
Reuters · 04/04 18:02
BUZZ-U.S. STOCKS ON THE MOVE-Delta Air Lines, Alternus Clean Energy, US banks
Wall Street's main stock indexes advanced on Thursday. Dow Jones Industrial Average was up 0.41% at 39,288.94. Delta Air Lines and Alternus Clean Energy were among the biggest decliners on the New York Stock Exchange. The Nasdaq composite and S&P 500 were both up.
Reuters · 04/04 15:52
BUZZ-eFFECTOR Therapeutics slumps on plans to stop development of lung cancer therapy
EFFECTOR Therapeutics falls 78.6% to a record low of $3.53. Company says it will stop development of lung cancer therapy. Shares of eFFECTor are down 69.8% this year. Co says there was modest activity from tomivosertib in small cell lung cancer.
Reuters · 04/04 13:41
SHARES OF EFFECTOR THERAPEUTICS DOWN 78.6% ON PLANS TO STOP DEVELOPMENT OF LUNG CANCER THERAPY
Reuters · 04/04 13:31
BUZZ-U.S. STOCKS ON THE MOVE-Meta, Intuitive Machines, Conagra Brands
Dow e-minis set for a higher open on Thursday. Recent economic reports boosted prospect of monetary policy easing later this year. Meta Platforms, Intuitive Machines, Conagra Brands and BlackBerry among top stocks on the move. The top three NYSE percentage gainers premarket were Allurion Technologies, Levi Strauss and BlackBerry.
Reuters · 04/04 13:25
SHARES OF EFFECTOR THERAPEUTICS DOWN 75% PREMARKET AFTER CO DISCONTINUES EXPERIMENTAL LUNG CANCER THERAPY
Reuters · 04/04 13:01
SHARES OF EFFECTOR THERAPEUTICS RESUME TRADING PREMARKET
Reuters · 04/04 13:01
EFFECTOR THERAPEUTICS:TO REPORT ADDITIONAL DATA, INCLUDING RECOMMENDED PHASE 2 DOSE, FOR ZOTATIFIN COMBINED WITH FULVESTRANT & ABEMACICLIB IN H2 2024
Reuters · 04/04 12:30
EFFECTOR THERAPEUTICS INC: OVERALL SURVIVAL RESULTS REMAIN IMMATURE
Reuters · 04/04 12:30
EFFECTOR THERAPEUTICS INC: DO NOT SEE AN OBVIOUS PATH FORWARD TO CONTINUE DEVELOPING TOMIVOSERTIB IN FRONTLINE NSCLC
Reuters · 04/04 12:30
EFFECTOR THERAPEUTICS SHARES HALTED FOR NEWS PENDING PREMARKET
Reuters · 04/04 12:26
Weekly Report: what happened at EFTRW last week (0325-0329)?
Weekly Report · 04/01 12:02
Weekly Report: what happened at EFTRW last week (0318-0322)?
Weekly Report · 03/25 12:06
Weekly Report: what happened at EFTRW last week (0311-0315)?
Weekly Report · 03/18 12:04
Weekly Report: what happened at EFTRW last week (0304-0308)?
Weekly Report · 03/11 11:59
More
Webull provides a variety of real-time EFTRW stock news. You can receive the latest news about Effector Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About EFTRW
eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology drugs, such as selective translation regulator inhibitors (STRIs). The Company uses a selective translation regulation technology platform to internally discover a portfolio of small molecule STRI product candidates. Its product candidates target the eIF4F complex and its activating kinase, MNK. The Company’s lead product candidate, tomivosertib, is an inhibitor of MNK, and is being evaluated in combination with KEYTRUDA (pembrolizumab), an FDA-approved inhibitor of programmed cell death protein 1 (PD-1) in a randomized Phase 2b clinical trial in patients with metastatic non-small cell lung cancer (NSCLC). Its second product candidate, zotatifin, is an inhibitor of eIF4A, a component of the eIF4F complex, and is being evaluated in a Phase 1/2 clinical trial in patients with certain solid tumors. Its third program is focused on developing inhibitors of eIF4E.